Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim; Sin Gon Kim; Doo Man Kim; Jeong Taek Woo; Hak Chul Jang; Choon Hee Chung; Kyung Soo Ko; Jeong Hyun Park; Yong Soo Park; Sang Jin Kim; Dong Seop Choi

doi:10.1016/j.diabres.2015.09.009

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim
, Sin Gon Kim
, Doo Man Kim
, Jeong Taek Woo
, Hak Chul Jang
, Choon Hee Chung
, Kyung Soo Ko
, Jeong Hyun Park
, Yong Soo Park
, Sang Jin Kim
, Dong Seop Choi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

Original language	English
Pages (from-to)	e27-e30
Journal	Diabetes Research and Clinical Practice
Volume	110
Issue number	3
DOIs	https://doi.org/10.1016/j.diabres.2015.09.009
Publication status	Published - 2015 Dec 1
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ireland Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Clinical trial
Lobeglitazone
Randomised trial
Thiazolidinediones

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.diabres.2015.09.009

Cite this

Kim, S. H., Kim, S. G., Kim, D. M., Woo, J. T., Jang, H. C., Chung, C. H., Ko, K. S., Park, J. H., Park, Y. S., Kim, S. J., & Choi, D. S. (2015). Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. Diabetes Research and Clinical Practice, 110(3), e27-e30. https://doi.org/10.1016/j.diabres.2015.09.009

@article{511aa34433cd481b80d1fa90a585b53d,

title = "Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study",

abstract = "We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.",

keywords = "Clinical trial, Lobeglitazone, Randomised trial, Thiazolidinediones",

author = "Kim, \{Sun Hwa\} and Kim, \{Sin Gon\} and Kim, \{Doo Man\} and Woo, \{Jeong Taek\} and Jang, \{Hak Chul\} and Chung, \{Choon Hee\} and Ko, \{Kyung Soo\} and Park, \{Jeong Hyun\} and Park, \{Yong Soo\} and Kim, \{Sang Jin\} and Choi, \{Dong Seop\}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.diabres.2015.09.009",

language = "English",

volume = "110",

pages = "e27--e30",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks

T2 - An open-label extension study

AU - Kim, Sun Hwa

AU - Kim, Sin Gon

AU - Kim, Doo Man

AU - Woo, Jeong Taek

AU - Jang, Hak Chul

AU - Chung, Choon Hee

AU - Ko, Kyung Soo

AU - Park, Jeong Hyun

AU - Park, Yong Soo

AU - Kim, Sang Jin

AU - Choi, Dong Seop

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

AB - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

KW - Clinical trial

KW - Lobeglitazone

KW - Randomised trial

KW - Thiazolidinediones

UR - https://www.scopus.com/pages/publications/84955202578

U2 - 10.1016/j.diabres.2015.09.009

DO - 10.1016/j.diabres.2015.09.009

M3 - Article

C2 - 26458774

AN - SCOPUS:84955202578

SN - 0168-8227

VL - 110

SP - e27-e30

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 3

ER -

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this